Date: Wednesday, March 23rd, 2022
This presentation focused on new therapeutic entities and their potential to disrupt drug spending and/or current clinical practice. Examples included medications for acute and chronic indications, as well as biosimilars and vaccines.
The CPS clinical development process from surveillance to resource delivery was discussed.
Topics included:
• Current areas of focus in new drug approvals
• The financial and clinical impact of drugs recently approved
• Best practices to optimize medication management
Valerie Sheehan, Vice President, Clinical Program Development, CPS
Karen Lee, Vice President, Clinical Program Development, CPS